Agree completely. One of the key appointments was a VP Clinical Development, specifically to support the clinical development of the ophthalmology and neuro programs, ie phase 1 and beyond. His background is very strong in design and execution of Phase 1/2 studies in particular. I believe the Company is confident the tox results will permit progression to Phase 1 trials shortly. They indicated previously that it was going well so far then.
Even with positive tox results only, EmtinB is an attractive target for big Pharma, especially with the near term glaucoma opportunity. Positive Phase 1 results would further boost value to NSB in any transaction but wouldn't necessarily be required for it to happen.
Big year coming up, I reckon this will be trading over $1 during 2021.
GLTAH
NSB Price at posting:
26.5¢ Sentiment: Buy Disclosure: Held
